Colombian experience with transcatheter aortic valve implantation of medtronic corevalve

Antonio E. Dager, Rutger Jan Nuis, Bernardo Caicedo, Jaime A. Fonseca, Camilo Arana, Lidsa R N Cruz, Luis M. Benitez, Carlos A. Nader, Eduardo Duenas, Eduardo De Marchena, William W. O'Neill, Peter P. de Jaegere

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 ± 6 yr; men, 58%) underwent TAVI with the Medtronic CoreValve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results. Predicted mortality rates were 25% (interquartile range, 17%-34%) according to logistic EuroSCORE and 6% (interquartile range, 3%-8%) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9% (3 intraprocedural deaths, 5 total). The combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threatening bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury [stage 3], 2%). Eight patients (15%) required post-implantation balloon dilation and 2 (4%) required valve-in-valve implantation, for a technical device success rate of 77%. Mean peak transvalvular gradient decreased from 74 ± 29 to 17 ± 8 mmHg and mean transvalvular gradient from 40 ± 17 to 8 ± 4 mmHg (both P=0.001). Moderate or severe aortic regurgitation decreased from 32% to 18% (P=0.12) and mitral regurgitation from 32% to 13% (P=0.002). The 1-year survival rate was 81%. We found that TAVI with the CoreValve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30% of the patients.

Original languageEnglish
Pages (from-to)351-358
Number of pages8
JournalTexas Heart Institute Journal
Volume39
Issue number3
StatePublished - Jul 26 2012

Fingerprint

Aortic Valve Stenosis
Aortic Valve Insufficiency
Mortality
Mitral Valve Insufficiency
Aortic Valve
Acute Kidney Injury
Surgical Instruments
Information Systems
Prostheses and Implants
Blood Vessels
Dilatation
Survival Rate
Stroke
Myocardial Infarction
Transcatheter Aortic Valve Replacement
Hemorrhage
Safety
Equipment and Supplies
Research

Keywords

  • Aortic valve stenosis/complications/mortality/surgery
  • Comorbidity
  • Heart valve prosthesis implantation/methods
  • Postoperative complications/etiology/prevention control
  • Registries
  • Risk factors
  • Treatment outcome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dager, A. E., Nuis, R. J., Caicedo, B., Fonseca, J. A., Arana, C., Cruz, L. R. N., ... de Jaegere, P. P. (2012). Colombian experience with transcatheter aortic valve implantation of medtronic corevalve. Texas Heart Institute Journal, 39(3), 351-358.

Colombian experience with transcatheter aortic valve implantation of medtronic corevalve. / Dager, Antonio E.; Nuis, Rutger Jan; Caicedo, Bernardo; Fonseca, Jaime A.; Arana, Camilo; Cruz, Lidsa R N; Benitez, Luis M.; Nader, Carlos A.; Duenas, Eduardo; De Marchena, Eduardo; O'Neill, William W.; de Jaegere, Peter P.

In: Texas Heart Institute Journal, Vol. 39, No. 3, 26.07.2012, p. 351-358.

Research output: Contribution to journalArticle

Dager, AE, Nuis, RJ, Caicedo, B, Fonseca, JA, Arana, C, Cruz, LRN, Benitez, LM, Nader, CA, Duenas, E, De Marchena, E, O'Neill, WW & de Jaegere, PP 2012, 'Colombian experience with transcatheter aortic valve implantation of medtronic corevalve', Texas Heart Institute Journal, vol. 39, no. 3, pp. 351-358.
Dager AE, Nuis RJ, Caicedo B, Fonseca JA, Arana C, Cruz LRN et al. Colombian experience with transcatheter aortic valve implantation of medtronic corevalve. Texas Heart Institute Journal. 2012 Jul 26;39(3):351-358.
Dager, Antonio E. ; Nuis, Rutger Jan ; Caicedo, Bernardo ; Fonseca, Jaime A. ; Arana, Camilo ; Cruz, Lidsa R N ; Benitez, Luis M. ; Nader, Carlos A. ; Duenas, Eduardo ; De Marchena, Eduardo ; O'Neill, William W. ; de Jaegere, Peter P. / Colombian experience with transcatheter aortic valve implantation of medtronic corevalve. In: Texas Heart Institute Journal. 2012 ; Vol. 39, No. 3. pp. 351-358.
@article{c919f699eab4421588d7ce88e05fcd1c,
title = "Colombian experience with transcatheter aortic valve implantation of medtronic corevalve",
abstract = "At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 ± 6 yr; men, 58{\%}) underwent TAVI with the Medtronic CoreValve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results. Predicted mortality rates were 25{\%} (interquartile range, 17{\%}-34{\%}) according to logistic EuroSCORE and 6{\%} (interquartile range, 3{\%}-8{\%}) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9{\%} (3 intraprocedural deaths, 5 total). The combined 30-day safety endpoint was 30{\%} (major vascular sequelae, 23{\%}; life-threatening bleeding, 12{\%}; myocardial infarction, 4{\%}; major stroke, 4{\%}; and acute kidney injury [stage 3], 2{\%}). Eight patients (15{\%}) required post-implantation balloon dilation and 2 (4{\%}) required valve-in-valve implantation, for a technical device success rate of 77{\%}. Mean peak transvalvular gradient decreased from 74 ± 29 to 17 ± 8 mmHg and mean transvalvular gradient from 40 ± 17 to 8 ± 4 mmHg (both P=0.001). Moderate or severe aortic regurgitation decreased from 32{\%} to 18{\%} (P=0.12) and mitral regurgitation from 32{\%} to 13{\%} (P=0.002). The 1-year survival rate was 81{\%}. We found that TAVI with the CoreValve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30{\%} of the patients.",
keywords = "Aortic valve stenosis/complications/mortality/surgery, Comorbidity, Heart valve prosthesis implantation/methods, Postoperative complications/etiology/prevention control, Registries, Risk factors, Treatment outcome",
author = "Dager, {Antonio E.} and Nuis, {Rutger Jan} and Bernardo Caicedo and Fonseca, {Jaime A.} and Camilo Arana and Cruz, {Lidsa R N} and Benitez, {Luis M.} and Nader, {Carlos A.} and Eduardo Duenas and {De Marchena}, Eduardo and O'Neill, {William W.} and {de Jaegere}, {Peter P.}",
year = "2012",
month = "7",
day = "26",
language = "English",
volume = "39",
pages = "351--358",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "3",

}

TY - JOUR

T1 - Colombian experience with transcatheter aortic valve implantation of medtronic corevalve

AU - Dager, Antonio E.

AU - Nuis, Rutger Jan

AU - Caicedo, Bernardo

AU - Fonseca, Jaime A.

AU - Arana, Camilo

AU - Cruz, Lidsa R N

AU - Benitez, Luis M.

AU - Nader, Carlos A.

AU - Duenas, Eduardo

AU - De Marchena, Eduardo

AU - O'Neill, William W.

AU - de Jaegere, Peter P.

PY - 2012/7/26

Y1 - 2012/7/26

N2 - At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 ± 6 yr; men, 58%) underwent TAVI with the Medtronic CoreValve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results. Predicted mortality rates were 25% (interquartile range, 17%-34%) according to logistic EuroSCORE and 6% (interquartile range, 3%-8%) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9% (3 intraprocedural deaths, 5 total). The combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threatening bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury [stage 3], 2%). Eight patients (15%) required post-implantation balloon dilation and 2 (4%) required valve-in-valve implantation, for a technical device success rate of 77%. Mean peak transvalvular gradient decreased from 74 ± 29 to 17 ± 8 mmHg and mean transvalvular gradient from 40 ± 17 to 8 ± 4 mmHg (both P=0.001). Moderate or severe aortic regurgitation decreased from 32% to 18% (P=0.12) and mitral regurgitation from 32% to 13% (P=0.002). The 1-year survival rate was 81%. We found that TAVI with the CoreValve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30% of the patients.

AB - At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 ± 6 yr; men, 58%) underwent TAVI with the Medtronic CoreValve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results. Predicted mortality rates were 25% (interquartile range, 17%-34%) according to logistic EuroSCORE and 6% (interquartile range, 3%-8%) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9% (3 intraprocedural deaths, 5 total). The combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threatening bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury [stage 3], 2%). Eight patients (15%) required post-implantation balloon dilation and 2 (4%) required valve-in-valve implantation, for a technical device success rate of 77%. Mean peak transvalvular gradient decreased from 74 ± 29 to 17 ± 8 mmHg and mean transvalvular gradient from 40 ± 17 to 8 ± 4 mmHg (both P=0.001). Moderate or severe aortic regurgitation decreased from 32% to 18% (P=0.12) and mitral regurgitation from 32% to 13% (P=0.002). The 1-year survival rate was 81%. We found that TAVI with the CoreValve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30% of the patients.

KW - Aortic valve stenosis/complications/mortality/surgery

KW - Comorbidity

KW - Heart valve prosthesis implantation/methods

KW - Postoperative complications/etiology/prevention control

KW - Registries

KW - Risk factors

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84864101264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864101264&partnerID=8YFLogxK

M3 - Article

C2 - 22719143

AN - SCOPUS:84864101264

VL - 39

SP - 351

EP - 358

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 3

ER -